CADL (STOCKS)
Candel Therapeutics, Inc. Common Stock
$4.909700
+0.079700 (+1.65%)
Prev close: $4.830000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Paul-Peter Tak
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $355.98M
- Employees
- 38
- P/E (TTM)
- -6.95
- P/B (TTM)
- 5.12
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
8
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.54 | $-0.25 | -0.2892 | -115.31% |
|
Sep 2025 (Q3)
|
$-0.21 | $-0.19 | -0.0212 | -11.23% |
|
Jun 2025 (Q2)
|
$-0.09 | $-0.17 | +0.0834 | +48.10% |
|
Mar 2025 (Q1)
|
$0.13 | $-0.31 | +0.4360 | +142.48% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $10.08M |
| Operating Expenses | $48.27M |
| Research and Development | $30.50M |
| Other Operating Expenses | $17.77M |
| Operating Income/Loss | -$48.27M |
| Income/Loss From Continuing Operations After Tax | -$38.18M |
| Income/Loss From Continuing Operations Before Tax | -$38.18M |
| Income Tax Expense/Benefit | $0.00 |
| Interest Expense, Operating | $2.12M |
| Net Income/Loss | -$38.18M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$38.18M |
| Net Income/Loss Available To Common Stockholders, Basic | -$38.18M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.72 |
| Diluted Earnings Per Share | -$0.72 |
| Basic Average Shares | 52,958,644 |
| Diluted Average Shares | 52,958,644 |
| Assets | $125.20M |
| Current Assets | $121.39M |
| Noncurrent Assets | $3.81M |
| Fixed Assets | $1.64M |
| Other Non-current Assets | $2.16M |
| Liabilities | $73.27M |
| Current Liabilities | $9.00M |
| Accounts Payable | $1.13M |
| Wages | $3.38M |
| Other Current Liabilities | $4.48M |
| Noncurrent Liabilities | $64.28M |
| Equity | $51.92M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $51.92M |
| Liabilities And Equity | $125.20M |
| Net Cash Flow From Operating Activities | -$38.31M |
| Net Cash Flow From Operating Activities, Continuing | -$38.31M |
| Net Cash Flow From Investing Activities | -$560.00K |
| Net Cash Flow From Investing Activities, Continuing | -$560.00K |
| Net Cash Flow From Financing Activities | $56.10M |
| Net Cash Flow From Financing Activities, Continuing | $56.10M |
| Net Cash Flow | $17.23M |
| Net Cash Flow, Continuing | $17.23M |
| Comprehensive Income/Loss | -$38.18M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$38.18M |
| Other Comprehensive Income/Loss | $0.00 |